Finding New Drugs Is Laborious. This AI Startup Is Skipping The Lab Work
AI drug discovery startup Superluminal Medicine uses generative AI algorithms and molecular simulations to design target-specific drug…
AI drug discovery startup Superluminal Medicine uses generative AI algorithms and molecular simulations to design target-specific drug candidates entirely in software before conducting physical experiments. By replacing early wet-lab trial-and-error screening with high-speed computational modeling, the company aims to significantly shorten the years-long timeline and high costs typically required to identify viable drug leads. While computational predictions eliminate initial physical testing bottlenecks, candidates identified by AI must still undergo extensive laboratory validation, pre-clinical testing, and human trials to prove safety and efficacy.